Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03893539 · ClinicalTrials.gov registry record · NA
Clinical Utility for Ion Endoluminal System
A NA study of Lung Cancer and Lung Diseases, sponsored by Intuitive Surgical.
- Active
- Registry status
- NA
- Development phase
- 365
- Enrollment target
- 6
- Study locations
NCT03893539: Active NA study of Lung Cancer and Lung Diseases, sponsored by Intuitive Surgical.
NCT03893539 is a NA study of Lung Cancer and Lung Diseases that is active but no longer recruiting, run by Intuitive Surgical. The registered enrollment target is 365 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (61% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03893539, a NA study of Lung Cancer and Lung Diseases, is active but no longer recruiting, sponsored by Intuitive Surgical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 365 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this prospective, multi-center, single-arm, clinical study is to evaluate the clinical utility and performance of the FDA-cleared Ion™ Endoluminal System ("Ion") for bronchoscopically approaching and facilitating the tissue sampling of pulmonary nodules.
Conditions Studied
Interventions
- DEVICE Ion Endoluminal System™
Study Locations (6)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconness Medical Center - Boston
Michigan
- Henry Ford Health System - Detroit
Minnesota
- Mayo Clinic - Rochester
North Carolina
- FirstHealth Moore Regional Hospital - Pinehurst
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2019-03-29 |
| Est. Completion | 2024-05 |
| Phase | NA |
What the registry record for NCT03893539 still lists
NCT03893539 is an interventional study that assigns participants to a tested intervention. The registered 365 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (61% lower).
The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ion Endoluminal System™ is the first listed.
NCT03893539 lists 6 locations in 5 states (Massachusetts, Michigan, Minnesota).
Frequently Asked Questions
What is clinical trial NCT03893539 about?
NCT03893539 is a clinical study titled "Clinical Utility for Ion Endoluminal System". The goal of this prospective, multi-center, single-arm, clinical study is to evaluate the clinical utility and performance of the FDA-cleared Ion™ Endoluminal System ("Ion") for bronchoscopically approaching and facilitating the tissue sampling of pulmonary nodules.
What is the current status of trial NCT03893539?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 365 participants. The study started on 2019-03-29. Estimated completion is 2024-05.
What conditions does trial NCT03893539 study?
This clinical trial studies the following conditions: Lung Cancer, Lung Diseases, Pulmonary Nodule.
What interventions are being tested in trial NCT03893539?
The interventions under investigation include: Ion Endoluminal System™ (DEVICE).
Who is sponsoring clinical trial NCT03893539?
This trial is sponsored by Intuitive Surgical, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03893539 being conducted?
This trial has 6 study locations across Massachusetts, Michigan, Minnesota, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03893539's enrollment target sits among peer trials
365 86th of 409 higher than 324 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
- NCT05303519 · 365 participants · Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NCT05592626 · 365 participants · Phase 1
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI